Condition:
The purpose of this study is to evaluate the effects of the study medication, memantine (placebo, 20 mg or 40 mg/day) on alcohol drinking behavior in a laboratory setting in which participants are given an initial drink of alcohol followed by the choice to drink up to 12 more drinks over a three-hour period. We hypothesize that memantine will reduce craving and number of drinks consumed prior to and after exposure to the initial drink of alcohol and during the three hour drinking period. We will also evaluate the influence of family history of alcoholism on the efficacy of memantine in reducing alcohol drinking behavior.
Dates: June 2006 -
Study Status: Recruiting
Ages Eligible: 21 Years - 50 Years
Gender Eligible: Both
Inclusion Criteria:
Exclusion Criteria:
Sponsors:
Phase: Phase 2
First Received: February 27, 2008
Last Updated: January 22, 2010
Clinicaltrials.gov ID:
NCT00630955
Study HIC # 0602001068
Condition:
Interventions: Drug: memantine;
Drug: Memantine;
Drug: Placebo
The purpose of this study is to evaluate the effects of the study medication, memantine (placebo, 20 mg or 40 mg/day) on alcohol drinking behavior in a laboratory setting in which participants are given an initial drink of alcohol followed by the choice to drink up to 12 more drinks over a three-hour period. We hypothesize that memantine will reduce craving and number of drinks consumed prior to and after exposure to the initial drink of alcohol and during the three hour drinking period. We will also evaluate the influence of family history of alcoholism on the efficacy of memantine in reducing alcohol drinking behavior.
Dates: June 2006 -
Study Status: Recruiting
Ages Eligible: 21 Years - 50 Years
Gender Eligible: Both
Inclusion Criteria:
- Ages 21-50
- Able to read English at 6th grade level or higher and to complete study evaluations
- Regular alcohol drinker
Exclusion Criteria:
- Individuals who are seeking alcohol treatment
- Medical conditions that would contraindicate the use of memantine
- Regular use of other substances
Sponsors:
Phase: Phase 2
First Received: February 27, 2008
Last Updated: January 22, 2010
Clinicaltrials.gov ID:
NCT00630955
Study HIC # 0602001068
Dana A Cavallo, Ph.D.
2039747607
dana.cavallo@yale.edu
Tricia Dahl, B.A.
2039747599
tricia.dahl@yale.edu
Krishnan-Sarin, Suchitra
Principal Investigator
HIC # 0805003779